Precision BioSciences (DTIL) Expected to Announce Earnings on Tuesday

Precision BioSciences (NASDAQ:DTIL) will likely be posting its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Precision BioSciences to post earnings of ($0.21) per share and revenue of $9.0750 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

Precision BioSciences Price Performance

Shares of Precision BioSciences stock opened at $6.52 on Tuesday. The company has a current ratio of 13.32, a quick ratio of 13.32 and a debt-to-equity ratio of 0.24. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $8.82. The company has a market cap of $161.24 million, a P/E ratio of -1.27 and a beta of 1.28. The company’s fifty day simple moving average is $4.48 and its two-hundred day simple moving average is $5.06.

Insiders Place Their Bets

In other Precision BioSciences news, insider J. Jefferson Smith sold 10,200 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $4.03, for a total transaction of $41,106.00. Following the completion of the transaction, the insider owned 110,184 shares of the company’s stock, valued at approximately $444,041.52. This trade represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO John Alexander Kelly sold 15,213 shares of the business’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total transaction of $61,308.39. Following the sale, the chief financial officer owned 106,448 shares in the company, valued at approximately $428,985.44. This trade represents a 12.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 93,845 shares of company stock worth $376,677. 4.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Precision BioSciences

Several hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in shares of Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after buying an additional 4,025 shares during the last quarter. Lynx1 Capital Management LP increased its position in shares of Precision BioSciences by 0.6% during the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock valued at $5,755,000 after acquiring an additional 6,545 shares in the last quarter. Quarry LP raised its holdings in Precision BioSciences by 15.1% in the 4th quarter. Quarry LP now owns 68,311 shares of the company’s stock worth $284,000 after acquiring an additional 8,936 shares during the last quarter. Engineers Gate Manager LP purchased a new position in Precision BioSciences in the 4th quarter worth approximately $43,000. Finally, Occudo Quantitative Strategies LP bought a new position in Precision BioSciences in the 4th quarter valued at approximately $52,000. Institutional investors own 37.99% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DTIL. Wall Street Zen raised shares of Precision BioSciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Jefferies Financial Group reissued a “buy” rating and issued a $19.00 price target on shares of Precision BioSciences in a research note on Friday, March 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Precision BioSciences currently has a consensus rating of “Hold” and an average price target of $39.50.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.